Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

379 ARTÍCULOS , VIENDO DEL 256 AL 270

An unusual adverse event from a common medication in an individual with dementia

Casiano V, Kalish VB, Unwin B.

J Am Geriatr Soc. 2014 Nov;62(11):2223-4. doi: 10.1111/jgs.13078.

The evolution of preclinical Alzheimer's disease: implications for prevention trials

Sperling R, Mormino E, Johnson K.

Neuron. 2014 Nov 5;84(3):608-22. doi: 10.1016/j.neuron.2014.10.038. Epub 2014 Nov 5.

Assessing cognition and function in Alzheimer's disease clinical trials: do we have the right tools?

Snyder PJ, Kahle-Wrobleski K, Brannan S, Miller DS, Schindler RJ, DeSanti S, Ryan JM, Morrison G, Grundman M, Chandler J, Caselli RJ, Isaac M, Bain L, Carrillo MC.

Alzheimers Dement. 2014 Nov;10(6):853-60. doi: 10.1016/j.jalz.2014.07.158. Epub 2014 Nov 15.

Effects of vitamin E on cognitive performance during ageing and in Alzheimer's disease

La Fata G, Weber P, Mohajeri MH.

Nutrients. 2014 Nov 28;6(12):5453-72. doi: 10.3390/nu6125453.

Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis

Matsunaga S, Kishi T, Iwata N.

Int J Neuropsychopharmacol. 2014 Dec 28;18(5):pyu115. doi: 10.1093/ijnp/pyu115.

[Drug development for overcoming dementia in Japan]

Nakamura H.

Rinsho Shinkeigaku. 2014;54(12):1181-3. doi: 10.5692/clinicalneurol.54.1181.

Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease - challenges and perspectives

Polidori MC, Nelles G.

Curr Pharm Des. 2014;20(18):3083-92. doi: 10.2174/13816128113196660706.

NMDA neurotransmission dysfunction in mild cognitive impairment and Alzheimer's disease

Lin CH, Huang YJ, Lin CJ, Lane HY, Tsai GE.

Curr Pharm Des. 2014;20(32):5169-79. doi: 10.2174/1381612819666140110115603.

The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer's disease: a randomised controlled study

de Waal H, Stam CJ, Lansbergen MM, Wieggers RL, Kamphuis PJ, Scheltens P, Maestú F, van Straaten EC.

PLoS One. 2014 Jan 27;9(1):e86558. doi: 10.1371/journal.pone.0086558. eCollection 2014.

Treating dementia and agitation

Small GW.

JAMA. 2014 Feb 19;311(7):677-8. doi: 10.1001/jama.2014.94.

Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial

Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG; CitAD Research Group.

JAMA. 2014 Feb 19;311(7):682-91. doi: 10.1001/jama.2014.93.

Functional brain connectivity using fMRI in aging and Alzheimer's disease

Dennis EL, Thompson PM.

Neuropsychol Rev. 2014 Mar;24(1):49-62. doi: 10.1007/s11065-014-9249-6. Epub 2014 Feb 23.

New applications of disease genetics and pharmacogenetics to drug development

Roses AD, Saunders AM, Lutz MW, Zhang N, Hariri AR, Asin KE, Crenshaw DG, Budur K, Burns DK, Brannan SK.

Curr Opin Pharmacol. 2014 Feb;14:81-9. doi: 10.1016/j.coph.2013.12.002. Epub 2014 Jan 3.

Cognitive subdomain responses to galantamine in Alzheimer's disease

Song J, Ahn IS, Kang HS, Myung W, Lee Y, Woo SY, Ku HM, Hwang TY, Carroll BJ, Kim DK.

J Nerv Ment Dis. 2014 Mar;202(3):253-9. doi: 10.1097/NMD.0000000000000107.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias